Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00861627 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
A Phase 2 study, sponsored by Oncolytics Biotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT00861627 is a Phase 2 study that has completed, run by Oncolytics Biotech. The registered enrollment target is 37 participants.
The verdict
NCT00861627, a Phase 2 study, has completed, sponsored by Oncolytics Biotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this Phase 2 study is to investigate whether intravenous administration of a wild type reovirus (REOLYSIN®) in combination with paclitaxel and carboplatin is effective and safe in the treatment of Non-Small Cell Lung Cancer with KRAS or EGFR activation.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- BIOLOGICAL REOLYSIN®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2009-03 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00861627
The ClinicalTrials.gov registry entry for NCT00861627 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oncolytics Biotech, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00861627 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00861627 about?
NCT00861627 is a clinical study titled "Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation". The purpose of this Phase 2 study is to investigate whether intravenous administration of a wild type reovirus (REOLYSIN®) in combination with paclitaxel and carboplatin is effective and safe in the treatment of Non-Small Cell Lung Cancer with KRAS or EGFR activation.
What is the current status of trial NCT00861627?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2009-03. Estimated completion is 2015-11.
What interventions are being tested in trial NCT00861627?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), REOLYSIN® (BIOLOGICAL).
Who is sponsoring clinical trial NCT00861627?
This trial is sponsored by Oncolytics Biotech, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.